uric acid has been researched along with Fibrosis in 61 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Fibrosis: Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 8.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
| "The current work explored the influences of nifuroxazide, an in vivo inhibitor of signal transducer and activator of transcription-3 (STAT-3) activation, on tubulointerstitial fibrosis in rats with obstructive nephropathy using unilateral ureteral obstruction (UUO) model." | 8.02 | Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-κB signaling, oxidative stress and inflammation. ( Hassan, NME; Said, E; Shehatou, GSG, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 8.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| " This study investigated the effects of two neutral CB1 receptor antagonists, AM6545 and AM4113, on nephropathy associated with metabolic syndrome (MetS)." | 8.02 | Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. ( Aldawsari, HM; Binmahfouz, L; Eid, BG; El-Aziz, GA; El-Bassossy, HM; Hanafy, A; Hasan, A; Makriyannis, A; Neamatallah, T; Vemuri, K, 2021) |
| " The effects of phloretin on renal function, fibrosis, oxidative stress, inflammation, and UA metabolism in HUA mice were evaluated." | 7.96 | Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption. ( Chen, Y; Cheng, J; Cui, D; Li, L; Liu, J; Liu, S; Lu, Y; Mao, R; Tang, M; Wang, C; Yuan, Y; Zhao, M, 2020) |
| "Several experimental studies implicate uric acid in renal injury and fibrosis." | 7.88 | Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies. ( Choi, HY; Huh, KH; Jeong, HJ; Kim, BS; Kim, DG; Kim, MS; Kim, YS; Lim, BJ, 2018) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 7.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| "Triclosan (TCS) is a ubiquitous antimicrobial used in daily consumer products." | 5.91 | Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders. ( Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023) |
| "Fibrosis is the culprit in the electrical derangement of the myocytes." | 5.91 | Uric acid significantly correlates with the presence of low-voltage areas at the endocardial mapping in patients with non-valvular atrial fibrillation. ( Baroni, M; Carbonaro, M; Ciampi, CM; Fortuna, M; Giannattasio, C; Gigli, L; Leidi, F; Maloberti, A; Mazzone, P; Paolucci, M; Testoni, A; Vargiu, S; Varrenti, M, 2023) |
| "Chloroquine (CQ) is an anti-inflammatory and disease-modifying anti-rheumatic drug (DMARD) utilized in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus." | 5.91 | Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet. ( Cui, J; Hong, P; Li, Z; Lin, J; Nie, K; Wan, J; Wu, X; Zhang, X, 2023) |
| "Calcitriol treatment attenuated the injury with reducing uric acid and creatinine levels, as well as tubular injury." | 5.62 | Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction ( Arefian, N; Juffrie, M; Perdana Putri, RG; Ratna Sari, DC; Romi, MM; Wahyu Setyaningsih, WA, 2021) |
| "Esculetin is a candidate urate-lowering drug with renoprotective activity and the ability to inhibit XO, promote excretion of UA, protect oxidative stress injury, and reduce renal fibrosis." | 5.56 | Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis. ( Huang, B; Kong, W; Meng, J; Wang, L; Wang, Y; Xie, Z; Yang, B; Zhang, T; Zhou, H, 2020) |
| "Preventing and treating renal fibrosis was an optimal treatment for hyperuricemia-induced kidney diseases." | 5.51 | Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Li, L; Liu, J; Ma, L; Pan, J; Shi, M, 2019) |
| "Renal fibrosis is a complication of kidney injury and associated with increased risk of morbidity and mortality." | 5.48 | Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. ( Begum, J; Kumar, D; Kumar, P; Lingaraju, MC; Mathesh, K; Sharma, A; Singh, TU; Thakur, R, 2018) |
| "Hyperuricemia is associated with the development of chronic kidney disease." | 5.46 | Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats. ( Beibei, T; Huijuan, W; Jianchun, M; Rui, S; Xiaoxu, C; Xinghui, L, 2017) |
| " The indirect effects involve a reduction in insulin levels and resistance, uric acid concentration, body weight, and blood pressure." | 4.98 | The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. ( Ito, M; Tanaka, T, 2018) |
| "Uric acid has promoted renal fibrosis and inflammation in experimental studies, but some studies have shown nephroprotective effects due to alleviated oxidative stress." | 4.31 | Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency. ( Eräranta, A; Honkanen, T; Kurra, V; Lakkisto, P; Mustonen, J; Myllymäki, J; Paavonen, T; Pörsti, I; Riutta, A; Tikkanen, I, 2023) |
| "Excessive serum uric acid (SUA) causes hyperuricemic nephropathy (HN), characterized by inflammatory infiltration and tubulointerstitial fibrosis." | 4.12 | Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway. ( Chen, Z; Guan, J; Guo, J; Hu, XG; Lan, T; Li, MH; Mo, JX; Wu, KR, 2022) |
| "Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 4.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
| "Treatment with STAT3 inhibitor S3I-201 improved renal dysfunction, reduced serum uric acid level, and delayed the progression of kidney fibrosis." | 4.02 | Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease. ( Fu, P; Guo, F; Ma, L; Pan, J; Shi, M, 2021) |
| "High levels of serum uric acid is closely associated with atrial fibrillation (AF); nonetheless, the detailed mechanisms remain unknown." | 4.02 | Increased Susceptibility of Atrial Fibrillation Induced by Hyperuricemia in Rats: Mechanisms and Implications. ( Li, Y; Liang, D; Liang, Z; Liu, H; Liu, Y; Su, M; Sun, L; Wang, D; Wei, Y; Yin, S; Zhang, G; Zhang, S; Zhao, J, 2021) |
| " This study investigated the effects of two neutral CB1 receptor antagonists, AM6545 and AM4113, on nephropathy associated with metabolic syndrome (MetS)." | 4.02 | Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome. ( Aldawsari, HM; Binmahfouz, L; Eid, BG; El-Aziz, GA; El-Bassossy, HM; Hanafy, A; Hasan, A; Makriyannis, A; Neamatallah, T; Vemuri, K, 2021) |
| "The current work explored the influences of nifuroxazide, an in vivo inhibitor of signal transducer and activator of transcription-3 (STAT-3) activation, on tubulointerstitial fibrosis in rats with obstructive nephropathy using unilateral ureteral obstruction (UUO) model." | 4.02 | Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-κB signaling, oxidative stress and inflammation. ( Hassan, NME; Said, E; Shehatou, GSG, 2021) |
| "Fisetin lowered uricemia, suppressed renal inflammatory response, and improved kidney fibrosis to protect against hyperuricemic nephropathy via modulation of STAT3 and TGF-β signaling pathways." | 4.02 | Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling. ( Fu, P; Guo, F; Ma, L; Ren, Q; Tao, S; Wang, B; Yang, L, 2021) |
| " The effects of API on renal function, inflammation, fibrosis, and uric acid (UA) metabolism in mice with HN were evaluated." | 4.02 | Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway. ( Cao, Y; Chen, Y; Huang, Q; Jiang, Y; Li, L; Li, Y; Luo, J; Pang, J; Wu, T; Zhang, L; Zhao, Z; Zhou, P, 2021) |
| " The present study assessed the ability of taurine (TAU) to alleviate or prevent AMK-induced nephrotoxicity if co-administrated with AMK focusing on inflammation, apoptosis, and fibrosis." | 4.02 | The nephroprotective properties of taurine-amikacin treatment in rats are mediated through HSP25 and TLR-4 regulation. ( Azmy, A; El-Amir, A; Madbouly, N; Salama, A, 2021) |
| " The effects of phloretin on renal function, fibrosis, oxidative stress, inflammation, and UA metabolism in HUA mice were evaluated." | 3.96 | Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption. ( Chen, Y; Cheng, J; Cui, D; Li, L; Liu, J; Liu, S; Lu, Y; Mao, R; Tang, M; Wang, C; Yuan, Y; Zhao, M, 2020) |
| "Although the clinical implication of hyperuricemia in chronic kidney disease has been an issue of active debate, recent data suggested a causative role of uric acid (UA) in the development of renal disease." | 3.88 | Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells. ( Kang, DH, 2018) |
| "Several experimental studies implicate uric acid in renal injury and fibrosis." | 3.88 | Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies. ( Choi, HY; Huh, KH; Jeong, HJ; Kim, BS; Kim, DG; Kim, MS; Kim, YS; Lim, BJ, 2018) |
| "Uric acid (UA) has been associated with renal fibrosis and progression of chronic kidney disease." | 3.85 | Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney. ( De Paul, AL; Latini, A; Mukdsi, JH; Remor, A; Romero, CA; Torres, AI, 2017) |
| " The effect of preventing hyperuricemia was determined by concomitant treatment with a xanthine oxidase inhibitor, allopurinol (CsAALP), or with a uricosuric, benzbromarone (CsABENZ), in drinking water." | 3.78 | Use of uric acid-lowering agents limits experimental cyclosporine nephropathy. ( Johnson, RJ; Mazali, FC; Mazzali, M, 2012) |
| " Blood urea nitrogen (BUN), serum creatinine (Scr), uric acid (UA) and proteinuria were evaluated." | 3.78 | Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. ( He, J; Pei, X; Sun, S; Wang, C; Wang, Y; Wu, J; Yu, M; Zhao, W; Zhu, B, 2012) |
| " Previous studies using uric acid-lowering drugs in normouricemic animals are not suitable to answer the effect of hyperuricemia on ventricular remodeling after myocardial infarction." | 3.77 | Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia. ( Chen, CC; Hsu, YJ; Lee, TM, 2011) |
| " This has led to the hypothesis that uric acid may contribute to renal fibrosis and progressive renal disease." | 3.76 | Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. ( Junwei, Y; Lei, J; Li, F; Mingxia, X; Ping, W; Ruoyun, T; Weichun, H; Xiaohua, W; Yang, Z, 2010) |
| "Uric acid crystal was found in four patients pleural effusion and stones in two patients' spittle which were consist of monosodium urate (MSU)." | 3.70 | [Pleural effusion of gout]. ( Han, Y; Liu, L; Zhang, K, 2000) |
| "Chloroquine (CQ) is an anti-inflammatory and disease-modifying anti-rheumatic drug (DMARD) utilized in treating autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus." | 1.91 | Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet. ( Cui, J; Hong, P; Li, Z; Lin, J; Nie, K; Wan, J; Wu, X; Zhang, X, 2023) |
| "Fibrosis is the culprit in the electrical derangement of the myocytes." | 1.91 | Uric acid significantly correlates with the presence of low-voltage areas at the endocardial mapping in patients with non-valvular atrial fibrillation. ( Baroni, M; Carbonaro, M; Ciampi, CM; Fortuna, M; Giannattasio, C; Gigli, L; Leidi, F; Maloberti, A; Mazzone, P; Paolucci, M; Testoni, A; Vargiu, S; Varrenti, M, 2023) |
| "Triclosan (TCS) is a ubiquitous antimicrobial used in daily consumer products." | 1.91 | Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders. ( Cai, Z; Cao, G; Chen, D; Chen, Y; Deng, C; Huang, W; Wang, T, 2023) |
| "Hyperuricemia is a critical threat to human health, and conventional medical treatment only aims to treat acute gouty arthritis." | 1.72 | Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis. ( Chen, X; Lu, Y; Lu, Z; Meng, F; Pang, X; Zhang, L; Zhao, H; Zhou, L, 2022) |
| "Calcitriol treatment attenuated the injury with reducing uric acid and creatinine levels, as well as tubular injury." | 1.62 | Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction ( Arefian, N; Juffrie, M; Perdana Putri, RG; Ratna Sari, DC; Romi, MM; Wahyu Setyaningsih, WA, 2021) |
| "Esculetin is a candidate urate-lowering drug with renoprotective activity and the ability to inhibit XO, promote excretion of UA, protect oxidative stress injury, and reduce renal fibrosis." | 1.56 | Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis. ( Huang, B; Kong, W; Meng, J; Wang, L; Wang, Y; Xie, Z; Yang, B; Zhang, T; Zhou, H, 2020) |
| "Hyperuricemia has been identified as an independent risk factor for chronic kidney disease (CKD) and is associated with the progression of kidney diseases." | 1.51 | Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia. ( Bao, W; Fang, L; Gu, H; Lin, T; Liu, N; Lu, J; Ma, S; Qiu, A; Shi, Y; Tao, M; Wang, Y; Xu, L; Zhuang, S, 2019) |
| "Preventing and treating renal fibrosis was an optimal treatment for hyperuricemia-induced kidney diseases." | 1.51 | Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. ( Feng, Y; Fu, P; Guo, F; Li, L; Liu, J; Ma, L; Pan, J; Shi, M, 2019) |
| "Renal fibrosis is a complication of kidney injury and associated with increased risk of morbidity and mortality." | 1.48 | Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. ( Begum, J; Kumar, D; Kumar, P; Lingaraju, MC; Mathesh, K; Sharma, A; Singh, TU; Thakur, R, 2018) |
| "Hyperuricemia is associated with the development of chronic kidney disease." | 1.46 | Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats. ( Beibei, T; Huijuan, W; Jianchun, M; Rui, S; Xiaoxu, C; Xinghui, L, 2017) |
| "Uric acid is a damage-associated molecular pattern (DAMP), released from ischemic tissues and dying cells which, when crystalized, is able to activate the NLRP3 inflammasome." | 1.46 | Soluble Uric Acid Activates the NLRP3 Inflammasome. ( Barbuto, JA; Braga, TT; Branco, P; Camara, NO; Castoldi, A; Correa-Costa, M; Davanso, MR; Forni, MF; Franklin, BS; Hiyane, MI; Kowaltowski, AJ; Latz, E; Ramos, RN, 2017) |
| "Hyperuricemia is an independent risk factor for CKD and contributes to kidney fibrosis." | 1.42 | EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. ( Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S, 2015) |
| "A cause for the tumoral calcinosis lesions in these turtles could not be determined; however, based on previous reports in this species, a species-specific predilection, in conjunction with unknown environmental factors, is suspected." | 1.39 | Tumoral calcinosis form of hydroxyapatite deposition disease in related red-bellied short-necked turtles, Emydura subglobosa. ( Bicknese, EJ; Burns, RE; Shiraki, R; Stalis, IH; Westropp, JL, 2013) |
| " The effects of casein or soya protein combined with palm or safflower-seed oil on various serum parameters and renal histology were investigated on hyperuricaemic rats." | 1.36 | Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats. ( Chiou, HY; Lai, SH; Lo, HC; Wang, YH; Yang, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.28) | 18.2507 |
| 2000's | 3 (4.92) | 29.6817 |
| 2010's | 28 (45.90) | 24.3611 |
| 2020's | 28 (45.90) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, J | 2 |
| Shi, M | 2 |
| Guo, F | 3 |
| Ma, L | 4 |
| Fu, P | 3 |
| Romi, MM | 1 |
| Arefian, N | 1 |
| Wahyu Setyaningsih, WA | 1 |
| Perdana Putri, RG | 1 |
| Juffrie, M | 1 |
| Ratna Sari, DC | 1 |
| Huang, H | 1 |
| Ding, R | 1 |
| Chen, Z | 2 |
| Yi, Z | 1 |
| Wang, H | 1 |
| Lv, Y | 1 |
| Bao, E | 1 |
| Tu, M | 1 |
| Hu, S | 1 |
| Lou, Z | 1 |
| Wei, H | 1 |
| Chen, L | 1 |
| Li, Q | 1 |
| Liang, X | 1 |
| Wang, K | 1 |
| Zhang, Y | 5 |
| Li, Y | 3 |
| Liu, Y | 3 |
| Xu, G | 1 |
| Chen, JS | 1 |
| Wang, MX | 1 |
| Wang, MM | 1 |
| Zhang, YK | 1 |
| Guo, X | 1 |
| Chen, YY | 1 |
| Zhang, MQ | 1 |
| Sun, JY | 1 |
| Liu, YF | 1 |
| Liu, C | 1 |
| Zhao, H | 1 |
| Chen, X | 1 |
| Zhang, L | 2 |
| Meng, F | 1 |
| Zhou, L | 1 |
| Pang, X | 1 |
| Lu, Z | 1 |
| Lu, Y | 4 |
| Zhou, X | 1 |
| Zhang, B | 1 |
| Zhao, X | 1 |
| Lin, Y | 1 |
| Zhuang, Y | 1 |
| Guo, J | 2 |
| Wang, S | 2 |
| Li, MH | 1 |
| Guan, J | 1 |
| Mo, JX | 1 |
| Wu, KR | 1 |
| Hu, XG | 1 |
| Lan, T | 1 |
| Yang, C | 1 |
| Su, HY | 1 |
| An, N | 1 |
| Wu, HL | 1 |
| Guo, XY | 1 |
| Li, ZH | 1 |
| Chen, XC | 1 |
| Zhu, SP | 1 |
| Wu, D | 1 |
| Li, HY | 1 |
| Pan, QJ | 1 |
| Liang, D | 2 |
| Liu, HF | 1 |
| Huang, W | 1 |
| Cao, G | 1 |
| Deng, C | 2 |
| Chen, Y | 4 |
| Wang, T | 1 |
| Chen, D | 1 |
| Cai, Z | 1 |
| Kurra, V | 1 |
| Eräranta, A | 1 |
| Paavonen, T | 1 |
| Honkanen, T | 1 |
| Myllymäki, J | 1 |
| Riutta, A | 1 |
| Tikkanen, I | 1 |
| Lakkisto, P | 1 |
| Mustonen, J | 1 |
| Pörsti, I | 1 |
| Baroni, M | 1 |
| Fortuna, M | 1 |
| Maloberti, A | 1 |
| Leidi, F | 1 |
| Ciampi, CM | 1 |
| Carbonaro, M | 1 |
| Testoni, A | 1 |
| Vargiu, S | 1 |
| Varrenti, M | 1 |
| Paolucci, M | 1 |
| Gigli, L | 1 |
| Giannattasio, C | 1 |
| Mazzone, P | 1 |
| Cui, J | 1 |
| Hong, P | 1 |
| Li, Z | 1 |
| Lin, J | 1 |
| Wu, X | 1 |
| Nie, K | 1 |
| Zhang, X | 1 |
| Wan, J | 1 |
| Sun, L | 2 |
| Liu, Q | 1 |
| Xue, M | 1 |
| Yan, H | 2 |
| Qiu, X | 1 |
| Tian, Y | 1 |
| Zhang, H | 2 |
| Liang, H | 1 |
| Lu, M | 1 |
| Yin, J | 1 |
| Xu, T | 1 |
| Dai, X | 1 |
| Liu, T | 1 |
| Shi, H | 1 |
| Mo, F | 1 |
| Sukhorukov, V | 1 |
| Orekhov, AN | 1 |
| Gao, S | 1 |
| Wang, L | 3 |
| Zhang, D | 1 |
| Cui, D | 1 |
| Liu, S | 1 |
| Tang, M | 1 |
| Zhao, M | 1 |
| Mao, R | 1 |
| Wang, C | 2 |
| Yuan, Y | 2 |
| Li, L | 4 |
| Cheng, J | 1 |
| Liu, J | 3 |
| Balakumar, P | 1 |
| Alqahtani, A | 1 |
| Khan, NA | 1 |
| Mahadevan, N | 1 |
| Dhanaraj, SA | 1 |
| Wang, Y | 3 |
| Kong, W | 1 |
| Zhang, T | 1 |
| Huang, B | 1 |
| Meng, J | 1 |
| Yang, B | 1 |
| Xie, Z | 1 |
| Zhou, H | 1 |
| Wang, D | 1 |
| Zhang, G | 1 |
| Liang, Z | 1 |
| Zhao, J | 1 |
| Yin, S | 1 |
| Su, M | 1 |
| Zhang, S | 2 |
| Wei, Y | 1 |
| Liu, H | 1 |
| Eid, BG | 1 |
| Neamatallah, T | 1 |
| Hanafy, A | 1 |
| El-Bassossy, HM | 1 |
| Binmahfouz, L | 1 |
| Aldawsari, HM | 1 |
| Hasan, A | 1 |
| El-Aziz, GA | 1 |
| Vemuri, K | 1 |
| Makriyannis, A | 1 |
| Hassan, NME | 1 |
| Said, E | 1 |
| Shehatou, GSG | 1 |
| Ren, Q | 1 |
| Tao, S | 1 |
| Wang, B | 1 |
| Yang, L | 1 |
| Zhao, Z | 1 |
| Luo, J | 1 |
| Jiang, Y | 1 |
| Huang, Q | 1 |
| Cao, Y | 1 |
| Zhou, P | 1 |
| Wu, T | 1 |
| Pang, J | 1 |
| Nakagawa, T | 1 |
| Sanchez-Lozada, LG | 1 |
| Andres-Hernando, A | 1 |
| Kojima, H | 1 |
| Kasahara, M | 1 |
| Rodriguez-Iturbe, B | 1 |
| Bjornstad, P | 1 |
| Lanaspa, MA | 1 |
| Johnson, RJ | 3 |
| Madbouly, N | 1 |
| Azmy, A | 1 |
| Salama, A | 1 |
| El-Amir, A | 1 |
| Cheng, D | 1 |
| An, X | 1 |
| Liao, G | 1 |
| Zhong, L | 1 |
| Du, P | 1 |
| Chen, M | 1 |
| Zhu, C | 1 |
| Romero, CA | 1 |
| Remor, A | 1 |
| Latini, A | 1 |
| De Paul, AL | 1 |
| Torres, AI | 1 |
| Mukdsi, JH | 1 |
| Huijuan, W | 1 |
| Xiaoxu, C | 1 |
| Rui, S | 1 |
| Xinghui, L | 1 |
| Beibei, T | 1 |
| Jianchun, M | 1 |
| Kang, DH | 2 |
| Ito, M | 1 |
| Tanaka, T | 2 |
| Thakur, R | 1 |
| Sharma, A | 1 |
| Lingaraju, MC | 1 |
| Begum, J | 1 |
| Kumar, D | 2 |
| Mathesh, K | 1 |
| Kumar, P | 1 |
| Singh, TU | 1 |
| Park, SK | 1 |
| Rosenthal, TR | 1 |
| Williams, JS | 1 |
| Shelton, JM | 1 |
| Takahashi, M | 1 |
| Bobulescu, IA | 1 |
| Kim, DG | 1 |
| Kim, BS | 1 |
| Choi, HY | 1 |
| Lim, BJ | 1 |
| Huh, KH | 1 |
| Kim, MS | 1 |
| Jeong, HJ | 1 |
| Kim, YS | 1 |
| Feng, Y | 1 |
| Shi, Y | 2 |
| Xu, L | 2 |
| Tao, M | 1 |
| Fang, L | 1 |
| Lu, J | 1 |
| Gu, H | 1 |
| Ma, S | 1 |
| Lin, T | 1 |
| Bao, W | 2 |
| Qiu, A | 2 |
| Zhuang, S | 2 |
| Liu, N | 2 |
| Song, LL | 1 |
| Zhang, XR | 1 |
| Song, YN | 1 |
| Dai, HZ | 1 |
| Burns, RE | 1 |
| Bicknese, EJ | 1 |
| Westropp, JL | 1 |
| Shiraki, R | 1 |
| Stalis, IH | 1 |
| Neuschwander-Tetri, BA | 1 |
| Zalewska, A | 1 |
| Knaś, M | 1 |
| Gińdzieńska-Sieśkiewicz, E | 1 |
| Waszkiewicz, N | 1 |
| Klimiuk, A | 1 |
| Litwin, K | 1 |
| Sierakowski, S | 1 |
| Waszkiel, D | 1 |
| Kim, IY | 1 |
| Lee, DW | 1 |
| Lee, SB | 1 |
| Kwak, IS | 1 |
| Jia, G | 1 |
| Habibi, J | 1 |
| Bostick, BP | 1 |
| DeMarco, VG | 1 |
| Aroor, AR | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, AT | 1 |
| Sowers, JR | 1 |
| Sibunruang, C | 1 |
| Ingsathit, A | 1 |
| Kantachuvesiri, P | 1 |
| Radinahamed, P | 1 |
| Rattanasiri, S | 1 |
| Pootracool, P | 1 |
| Kijvikai, K | 1 |
| Sumethkul, V | 1 |
| Kantachuvesiri, S | 1 |
| Yang, T | 1 |
| Xiong, C | 1 |
| Chin, YE | 1 |
| Cheng, SB | 1 |
| Lin, L | 1 |
| Yang, J | 2 |
| Zhang, J | 1 |
| Li, K | 1 |
| Huo, B | 1 |
| Dai, H | 1 |
| Zhang, W | 1 |
| Tan, W | 1 |
| He, Y | 1 |
| Ai, Z | 1 |
| Xu, R | 1 |
| Liu, W | 1 |
| Zhou, Q | 1 |
| Li, B | 1 |
| Huang, F | 1 |
| Yu, X | 1 |
| Yang, Q | 1 |
| Abdel-Daim, MM | 1 |
| El-Sayed, YS | 1 |
| Eldaim, MA | 1 |
| Ibrahim, A | 1 |
| Braga, TT | 1 |
| Forni, MF | 1 |
| Correa-Costa, M | 1 |
| Ramos, RN | 1 |
| Barbuto, JA | 1 |
| Branco, P | 1 |
| Castoldi, A | 1 |
| Hiyane, MI | 1 |
| Davanso, MR | 1 |
| Latz, E | 1 |
| Franklin, BS | 1 |
| Kowaltowski, AJ | 1 |
| Camara, NO | 1 |
| Lo, HC | 1 |
| Wang, YH | 1 |
| Chiou, HY | 1 |
| Lai, SH | 1 |
| Yang, Y | 1 |
| Yang, Z | 1 |
| Xiaohua, W | 1 |
| Lei, J | 1 |
| Ruoyun, T | 1 |
| Mingxia, X | 1 |
| Weichun, H | 1 |
| Li, F | 1 |
| Ping, W | 1 |
| Junwei, Y | 1 |
| Chen, CC | 1 |
| Hsu, YJ | 1 |
| Lee, TM | 1 |
| Mazali, FC | 1 |
| Mazzali, M | 2 |
| Butler, R | 1 |
| Inzunza, J | 1 |
| Suzuki, H | 1 |
| Fujii-Kuriyama, Y | 1 |
| Warner, M | 1 |
| Gustafsson, JÅ | 1 |
| He, J | 1 |
| Sun, S | 1 |
| Yu, M | 1 |
| Pei, X | 1 |
| Zhu, B | 1 |
| Wu, J | 1 |
| Zhao, W | 1 |
| Iwata, A | 1 |
| Miura, S | 1 |
| Ike, A | 1 |
| Sugihara, M | 1 |
| Nishikawa, H | 1 |
| Kawamura, A | 1 |
| Saku, K | 1 |
| Stabellini, N | 1 |
| Storari, A | 1 |
| Aleotti, A | 1 |
| Fiocchi, O | 1 |
| Tarroni, G | 1 |
| Fabbian, F | 1 |
| Gilli, P | 1 |
| Gentile, S | 1 |
| Turco, S | 1 |
| Torella, R | 1 |
| George, J | 1 |
| Chandrakasan, G | 1 |
| Hughes, J | 1 |
| Kim, YG | 1 |
| Jefferson, JA | 1 |
| Gordon, KL | 1 |
| Lan, HY | 1 |
| Kivlighn, S | 1 |
| Zhang, K | 1 |
| Liu, L | 1 |
| Han, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Value of Uric Acid as Early Predictor of Lupus Nephritis in Assiut University Hospital[NCT05402735] | 100 participants (Anticipated) | Observational | 2022-06-15 | Recruiting | |||
| Pediatric Hypertension Registry (PHREG)[NCT03305562] | 179 participants (Actual) | Observational [Patient Registry] | 2017-09-20 | Terminated (stopped due to Study was a pilot study and the investigators received funding to initiate the main study) | |||
| The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)[NCT03310684] | 160 participants (Anticipated) | Observational | 2018-12-03 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for uric acid and Fibrosis
| Article | Year |
|---|---|
Mechanistic insights into hyperuricemia-associated renal abnormalities with special emphasis on epithelial-to-mesenchymal transition: Pathologic implications and putative pharmacologic targets.
Topics: Animals; Biomarkers; Cytokines; Epithelial-Mesenchymal Transition; Febuxostat; Fibrosis; Gout Suppre | 2020 |
Endogenous Fructose Metabolism Could Explain the Warburg Effect and the Protection of SGLT2 Inhibitors in Chronic Kidney Disease.
Topics: Animals; Cell Hypoxia; Diabetes Mellitus; Disease Progression; Fibrosis; Fructose; Glycolysis; Human | 2021 |
The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors.
Topics: Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glucose; Humans; Hypoglycemic Agen | 2018 |
Carbohydrate intake and nonalcoholic fatty liver disease.
Topics: Animals; Beverages; Clinical Trials as Topic; Dietary Carbohydrates; Fatty Liver; Fibrosis; Humans; | 2013 |
The role of uric acid in kidney fibrosis: experimental evidences for the causal relationship.
Topics: Animals; Disease Models, Animal; Fibrosis; Humans; Inflammation; Renal Insufficiency, Chronic; Uric | 2014 |
56 other studies available for uric acid and Fibrosis
| Article | Year |
|---|---|
Pharmacologic inhibiting STAT3 delays the progression of kidney fibrosis in hyperuricemia-induced chronic kidney disease.
Topics: Aminosalicylic Acids; Animals; Benzenesulfonates; Disease Models, Animal; Fibrosis; Hyperuricemia; K | 2021 |
Calcitriol Treatment Attenuates Uric Acid-Induced Kidney Injury via Super Oxide Dismutase-1 (SOD-1) Upregulation and Fibrosis Reduction
Topics: Animals; Calcitriol; Fibrosis; Hyperuricemia; Mice; Superoxide Dismutase-1; Up-Regulation; Uric Acid | 2021 |
Goose nephritic astrovirus infection increases autophagy, destroys intercellular junctions in renal tubular epithelial cells, and damages podocytes in the kidneys of infected goslings.
Topics: Animals; Astroviridae Infections; Autophagy; Avastrovirus; Fibrosis; Geese; Intercellular Junctions; | 2021 |
A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score.
Topics: Adult; Atrophy; Female; Fibrinogen; Fibrosis; Glomerulonephritis, IGA; Humans; Kidney Tubules; Male; | 2022 |
CD137L-macrophage induce lymphatic endothelial cells autophagy to promote lymphangiogenesis in renal fibrosis.
Topics: 4-1BB Ligand; Animals; Autophagy; Endothelial Cells; Female; Fibrosis; Glomerulonephritis, IGA; Huma | 2022 |
Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Iridoids; Kidney Diseases; Mice; Molecular Docking S | 2022 |
Lacticaseibacillus rhamnosus Fmb14 prevents purine induced hyperuricemia and alleviate renal fibrosis through gut-kidney axis.
Topics: Animals; Fibrosis; Humans; Hyperuricemia; Kidney; Kidney Diseases; Mice; Uric Acid | 2022 |
Chlorogenic Acid Prevents Hyperuricemia Nephropathy via Regulating TMAO-Related Gut Microbes and Inhibiting the PI3K/AKT/mTOR Pathway.
Topics: Animals; Chlorogenic Acid; Fibrosis; Gastrointestinal Microbiome; Hyperuricemia; Mammals; Methylamin | 2022 |
Fufang Zhenzhu Tiaozhi capsule ameliorates hyperuricemic nephropathy by inhibition of PI3K/AKT/NF-κB pathway.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Mice; NF-kappa B; Phosphatidylinositol 3-Kin | 2022 |
AMP-activated protein kinase α2 contributes to acute and chronic hyperuricemic nephropathy via renal urate deposition in a mouse model.
Topics: AMP-Activated Protein Kinases; Animals; Disease Models, Animal; Fibrosis; Hyperuricemia; Kidney; Kid | 2022 |
Adverse effects of triclosan on kidney in mice: Implication of lipid metabolism disorders.
Topics: Animals; Anti-Infective Agents; Corn Oil; Creatinine; Cytokines; Dimethyl Sulfoxide; Fatty Acids; Fi | 2023 |
Moderate hyperuricaemia ameliorated kidney damage in a low-renin model of experimental renal insufficiency.
Topics: Animals; Fibrosis; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Nephrectomy; Oxonic Acid; R | 2023 |
Uric acid significantly correlates with the presence of low-voltage areas at the endocardial mapping in patients with non-valvular atrial fibrillation.
Topics: Atrial Fibrillation; Cross-Sectional Studies; Fibrosis; Heart Atria; Humans; Uric Acid | 2023 |
Chloroquine inhibits NLRP3 inflammasomes activation and alleviates renal fibrosis in mouse model of hyperuricemic nephropathy with aggravation by a high-fat-diet.
Topics: Animals; Chloroquine; Creatinine; Diet, High-Fat; Fibrosis; Hyperuricemia; Inflammasomes; Kidney; Ki | 2023 |
Fucoidan from
Topics: Animals; Fibrosis; Hyperuricemia; Janus Kinase 2; Kidney; Laminaria; Mice; Polysaccharides; Renal In | 2023 |
Fuling-Zexie formula attenuates hyperuricemia-induced nephropathy and inhibits JAK2/STAT3 signaling and NLRP3 inflammasome activation in mice.
Topics: Albumins; Animals; Chromatography, Liquid; Fibrosis; Hyperuricemia; Inflammasomes; Inflammation; Int | 2024 |
Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption.
Topics: Animals; Cell Line; Cytokines; Fibrosis; Humans; Hyperuricemia; Inflammasomes; Inflammation; Kidney | 2020 |
Multiple-Purpose Connectivity Map Analysis Reveals the Benefits of Esculetin to Hyperuricemia and Renal Fibrosis.
Topics: Animals; Cell Nucleus; Disease Models, Animal; Down-Regulation; Fibrosis; Hep G2 Cells; Humans; Hype | 2020 |
Increased Susceptibility of Atrial Fibrillation Induced by Hyperuricemia in Rats: Mechanisms and Implications.
Topics: Actins; Animals; Apoptosis; Atrial Fibrillation; Atrial Remodeling; bcl-2-Associated X Protein; Benz | 2021 |
Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome.
Topics: Animals; Cytoprotection; Fibrosis; Inflammation; Kidney; Male; Metabolic Syndrome; Morpholines; Pyra | 2021 |
Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-κB signaling, oxidative stress and inflammation.
Topics: Animals; Fibrosis; Hydroxybenzoates; Inflammation; Kidney; Kidney Diseases; Male; NF-kappa B; Nitrof | 2021 |
Natural flavonol fisetin attenuated hyperuricemic nephropathy via inhibiting IL-6/JAK2/STAT3 and TGF-β/SMAD3 signaling.
Topics: Administration, Oral; Animals; Fibrosis; Flavonols; Gene Expression Regulation; Hyperuricemia; Inter | 2021 |
Apigenin ameliorates hyperuricemic nephropathy by inhibiting URAT1 and GLUT9 and relieving renal fibrosis via the Wnt/β-catenin pathway.
Topics: Animals; Apigenin; beta Catenin; Creatinine; Dose-Response Relationship, Drug; Fibrosis; Glucose Tra | 2021 |
The nephroprotective properties of taurine-amikacin treatment in rats are mediated through HSP25 and TLR-4 regulation.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Apoptosis; Blood Urea Nitrogen; Creatinine; Dose-Response | 2021 |
Mesenchymal stem cells transplantation attenuates hyperuricemic nephropathy in rats.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Culture Techniques; Cell Survival; Fibrosis; Hyperurice | 2021 |
microRNA-199a downregulation alleviates hyperuricemic nephropathy
Topics: Animals; beta Catenin; Down-Regulation; Fibrosis; Hyperuricemia; Kidney Diseases; MicroRNAs; PPAR ga | 2022 |
Uric acid activates NRLP3 inflammasome in an in-vivo model of epithelial to mesenchymal transition in the kidney.
Topics: Animals; Caspase 1; Epithelial-Mesenchymal Transition; Fibrosis; Inflammasomes; Inflammation; Kidney | 2017 |
Qi-Zhu-Xie-Zhuo-Fang reduces serum uric acid levels and ameliorates renal fibrosis in hyperuricemic nephropathy rats.
Topics: Animals; Collagen; Disease Progression; Down-Regulation; Drugs, Chinese Herbal; Extracellular Matrix | 2017 |
Hyperuricemia and Progression of Chronic Kidney Disease: Role of Phenotype Transition of Renal Tubular and Endothelial Cells.
Topics: Actins; Animals; Antioxidants; Capillaries; Disease Progression; Endothelial Cells; Epithelial-Mesen | 2018 |
Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats.
Topics: Adenine; Animals; Blood Urea Nitrogen; Collagen Type I; Connective Tissue Growth Factor; Creatinine; | 2018 |
Metabolic and cardiovascular effects of chronic mild hyperuricemia in rodents.
Topics: Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Chronic Disease; Fasti | 2018 |
Association between post-transplant uric acid level and renal allograft fibrosis: Analysis using Banff pathologic scores from renal biopsies.
Topics: Adult; Allografts; Biopsy; Female; Fibrosis; Graft Survival; Humans; Kidney; Kidney Transplantation; | 2018 |
Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy.
Topics: Animals; Blueberry Plants; Creatinine; Disease Models, Animal; Drugs, Chinese Herbal; Fibronectins; | 2019 |
Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia.
Topics: Animals; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Fibroblasts; Fibrosis; Histones; Hype | 2019 |
Theacrine attenuates myocardial fibrosis after myocardial infarction via the SIRT3/β-catenin/PPARγ pathway in estrogen-deficient mice.
Topics: Administration, Oral; Animals; Apoptosis; beta Catenin; Disease Models, Animal; Echocardiography; Es | 2019 |
Tumoral calcinosis form of hydroxyapatite deposition disease in related red-bellied short-necked turtles, Emydura subglobosa.
Topics: Animals; Apatites; Calcinosis; Calcium; Calcium Pyrophosphate; Crystallography; Durapatite; Female; | 2013 |
Salivary antioxidants in patients with systemic sclerosis.
Topics: Adult; Aged; Antioxidants; Atrophy; Case-Control Studies; Colorimetry; DMF Index; Female; Fibrosis; | 2014 |
Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet.
Topics: Allopurinol; Animals; Biomarkers; Diet, Western; Dietary Fats; Dietary Sucrose; Disease Models, Anim | 2015 |
Increased urine transforming growth factor β1 (TGF-β1) and serum uric acid are associated with an early decline of glomerular filtration rate in kidney transplant recipients.
Topics: Adult; Allografts; Female; Fibrosis; Follow-Up Studies; Glomerular Filtration Rate; Humans; Kidney; | 2015 |
EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Topics: Animals; Chemokines; Cytokines; Disease Progression; ErbB Receptors; Fibroblasts; Fibrosis; Gefitini | 2015 |
Nocturnal and Circadian Rhythm of Blood Pressure Is Associated with Renal Structure Damage and Function in Patients with IgAN.
Topics: Adolescent; Adult; Aorta, Thoracic; Asian People; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2016 |
Clinicopathologic features of IgA nephropathy patients with different levels of proteinuria.
Topics: Adult; Atrophy; Biopsy; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis, IGA; Glome | 2016 |
Nephroprotective efficacy of ceftriaxone against cisplatin-induced subchronic renal fibrosis in rats.
Topics: Actins; Animals; Biomarkers; Bromodeoxyuridine; Ceftriaxone; Cell Proliferation; Cisplatin; Creatini | 2017 |
Soluble Uric Acid Activates the NLRP3 Inflammasome.
Topics: Animals; Caspase 1; Cells, Cultured; Disease Models, Animal; Fibrosis; Inflammasomes; Interleukin-1b | 2017 |
Relative efficacy of casein or soya protein combined with palm or safflower-seed oil on hyperuricaemia in rats.
Topics: Albumins; Analysis of Variance; Animals; Blood Urea Nitrogen; Caseins; Cholesterol; Creatinine; Diet | 2010 |
Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells.
Topics: Animals; Blotting, Western; Cell Line; Disease Models, Animal; Epithelial Cells; Extracellular Matri | 2010 |
Impact of elevated uric acid on ventricular remodeling in infarcted rats with experimental hyperuricemia.
Topics: Allopurinol; Analysis of Variance; Animals; Antioxidants; Atrasentan; Biomarkers; Cyclic N-Oxides; D | 2011 |
Use of uric acid-lowering agents limits experimental cyclosporine nephropathy.
Topics: Allopurinol; Animals; Benzbromarone; Cell Proliferation; Cyclosporine; Enzyme Inhibitors; Fibrosis; | 2012 |
Uric acid stones in the urinary bladder of aryl hydrocarbon receptor (AhR) knockout mice.
Topics: Animals; Apoptosis; Cadherins; Fibrosis; Immunohistochemistry; In Situ Nick-End Labeling; Macrophage | 2012 |
Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model.
Topics: Animals; Atrophy; Biomarkers; Blood Urea Nitrogen; Bone Marrow Transplantation; Cell-Derived Micropa | 2012 |
Plasma pentraxin-3 levels are associated with coronary plaque vulnerability and are decreased by statin.
Topics: Aged; Angina, Stable; Atorvastatin; Biomarkers; C-Reactive Protein; Case-Control Studies; Chi-Square | 2012 |
Familial interstitial nephropathy without hyperuricemia.
Topics: Adult; Aged; Biopsy; Family Health; Female; Fibrosis; Humans; Kidney; Kidney Diseases; Male; Middle | 1994 |
Diabetes mellitus after liver transplantation: a possible relation with the nutritional status.
Topics: Albuminuria; Bilirubin; Blood Glucose; Blood Proteins; C-Peptide; Cyclosporine; Diabetes Mellitus, T | 1998 |
Biochemical abnormalities during the progression of hepatic fibrosis induced by dimethylnitrosamine.
Topics: Animals; Blood Glucose; Cholesterol; Creatinine; Dimethylnitrosamine; Fibrosis; Hydroxyproline; Insu | 2000 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism.
Topics: Animals; Blood Pressure; Crystallization; Fibrosis; Hypertension, Renal; Kidney; Kidney Diseases; Ma | 2001 |
[Pleural effusion of gout].
Topics: Adult; Aged; Female; Fibrosis; Gout; Humans; Lung; Lung Diseases; Male; Middle Aged; Pleural Effusio | 2000 |